Neurotech Pharmaceuticals' NT-501, a novel therapy for Macular Telangiectasia Type 2 (MacTel), faces a delayed FDA decision as the Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to March 18, 2025. The FDA requires additional time to review data submitted by Neurotech in response to recent requests. NT-501 (revakinagene taroretcel) is a Biologics License Application (BLA) seeking approval for this rare neurodegenerative disease.
NT-501: Encapsulated Cell Therapy for MacTel
NT-501 utilizes Neurotech's Encapsulated Cell Therapy (ECT) platform to deliver continuous doses of ciliary neurotrophic factor (CNTF) to the retina. The ECT platform involves a small, semi-permeable capsule containing allogeneic retinal pigment epithelium (RPE) cells genetically engineered to produce CNTF. This capsule is surgically implanted into the patient's vitreous, allowing essential nutrients to enter while enabling CNTF to exit and exert its neuroprotective effects. The semi-permeable membrane also shields the RPE cells from the host's immune system, ensuring long-term survival and functionality.
Clinical Trial Data
Two parallel Phase III trials (protocol A, NCT03316300; protocol B, NCT03319849) evaluated NT-501's efficacy, meeting the primary endpoint of reducing the rate of ellipsoid zone area loss, a key indicator of photoreceptor degeneration. Results indicated a 56.4% and 29.2% reduction in disease progression in the treatment groups of Protocol A and B, respectively. The implant demonstrated a favorable safety profile and was well-tolerated in both studies.
Macular Telangiectasia Type 2 (MacTel)
MacTel is a rare neurodegenerative disease characterized by localized retinal degeneration and secondary alterations in retinal vasculature. It typically affects both eyes, leading to a gradual decline in central vision. Currently, there are limited treatment options available, highlighting the unmet medical need for therapies like NT-501.
Company Statement
"We are committed to providing the Agency any information needed to complete the review of the NT-501 BLA," said Richard Small, Chief Executive Officer of Neurotech Pharmaceuticals. "Neurotech will continue in our effort to bring this important therapy to MacTel patients."
